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Background: Cancer-related genes show racial differences. Therefore, identification and characterization of DNA
copy number alteration regions in different racial groups helps to dissect the mechanism of tumorigenesis.
Methods: Array-comparative genomic hybridization (array-CGH) was analyzed for DNA copy number profile in 40
Asian and 20 Caucasian lung cancer patients. Three methods including MetaCore analysis for disease and pathway
correlations, concordance analysis between array-CGH database and the expression array database, and literature
search for copy number variation genes were performed to select novel lung cancer candidate genes. Four
candidate oncogenes were validated for DNA copy number and mRNA and protein expression by quantitative
polymerase chain reaction (qPCR), chromogenic in situ hybridization (CISH), reverse transcriptase-qPCR (RT-qPCR),
and immunohistochemistry (IHC) in more patients.
Results: We identified 20 chromosomal imbalance regions harboring 459 genes for Caucasian and 17 regions
containing 476 genes for Asian lung cancer patients. Seven common chromosomal imbalance regions harboring
117 genes, included gain on 3p13-14, 6p22.1, 9q21.13, 13q14.1, and 17p13.3; and loss on 3p22.2-22.3 and 13q13.3
were found both in Asian and Caucasian patients. Gene validation for four genes including ARHGAP19 (10q24.1)
functioning in Rho activity control, FRAT2 (10q24.1) involved in Wnt signaling, PAFAH1B1 (17p13.3) functioning in
motility control, and ZNF322A (6p22.1) involved in MAPK signaling was performed using qPCR and RT-qPCR. Mean
gene dosage and mRNA expression level of the four candidate genes in tumor tissues were significantly higher
than the corresponding normal tissues (P<0.001~P=0.06). In addition, CISH analysis of patients indicated that copy
number amplification indeed occurred for ARHGAP19 and ZNF322A genes in lung cancer patients. IHC analysis of
paraffin blocks from Asian Caucasian patients demonstrated that the frequency of PAFAH1B1 protein
overexpression was 68% in Asian and 70% in Caucasian.
Conclusions: Our study provides an invaluable database revealing common and differential imbalance regions at
specific chromosomes among Asian and Caucasian lung cancer patients. Four validation methods confirmed our
database, which would help in further studies on the mechanism of lung tumorigenesis.
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Lung cancer is the leading cause of cancer death world-
wide [1,2]. There is mounting evidence of difference be-
tween Asian and Caucasian lung cancer patients in clinical
and epidemiological aspects. For example, Lee et al. [3]
reported that lung cancer in Taiwan and South China is
characterized with a high percentage of female adenocar-
cinoma (ADC) and nonsmokers. In addition, response to
certain anticancer treatments such as gefitinib is much
greater in Asian patients than Caucasians [4]. How-
ever, these are rare large-scale attempts to identify the
molecular characteristics of lung cancer between Asian and
Caucasian. Therefore, identification and characterization of
the chromosome regions with DNA copy number alter-
ation in Western and Asian countries is important to
unravel the mechanism underlying lung tumorigenesis.
Genomic DNA copy number variation is a hallmark of
cancer and can lead to alteration in the expression and
functions of genes residing within the affected chromo-
somal region [5]. Such a segment in the tumor genome
may harbor either oncogenes or tumor suppressor genes
depending on whether they are present in increased or
decreased copy number, respectively. Identification of
regions with copy number aberrations and the genes
involved thus offers a basis for better understanding of
cancer development [6]. Array-comparative genomic
hybridization (array-CGH) can measure relative copy
number at specific loci, which are represented by arrays
of mapped bacterial artificial chromosomes (BAC)
clones, cDNA clones, or various oligonucleotide-based
formats [7-9]. The resolution of array-CGH is deter-
mined by the genomic spacing of the array elements
thus is much more improved compared to previous con-
ventional CGH [10-12].
To identify the chromosome regions with DNA copy
number alteration in patients from Western and Asian
countries, we constructed a non-gapped array containing
3604 BAC clones covering 18 lung cancer-related
chromosome imbalance hotspot regions identified in our
previous study [13]. DNA from 40 Asian and 20 Caucasian
non-small cell lung cancer (NSCLC) patients was analyzed
using this specialized array to identify lung cancer-related
genes either common or differential in these two ethnic
groups. The Bayes statistical and comparative genomic
approaches were used to identify genes with DNA copy
number alterations. Our study provides a comprehensive
database for chromosomal regions and genes with copy
number imbalance in both Asian and Caucasian lung
cancer patients. In addition, gene validation was performed
using quantitative polymerase chain reaction (qPCR),
reverse transcriptase-qPCR (RT-qPCR), chromogenic
in situ hybridization (CISH), and immunohistochemis-
try (IHC) on specimens from the Asian and Caucasian
lung cancer patients.Methods
Clinical samples preparation and DNA/RNA extraction
Tissues were collected after obtaining appropriate institu-
tional review board permission (VGHIRB No. 201001019IA)
and informed consent from the recruited patients. Surgically
resected tumor tissue and corresponding normal tissue were
collected from 40 patients diagnosed with primary non-
small cell lung cancer (NSCLC) admitted to Taipei Veterans
General Hospital, Taiwan. Twenty NSCLC tumor tissues
from Caucasian patients were obtained from the University
of Chicago, USA. The list of these 60 patients along with the
patients used for further validations is described in the
Additional file 1: Table S1. Histological classification
was determined according to the WHO classification
system and the tumor-node-metastasis system. Infor-
mation on the age, sex, tumor type, tumor stage and
smoking history of the patients was obtained from hos-
pital records. The genomic DNA was prepared using pro-
teinase K digestion and phenol-chloroform extraction.
Total RNA was prepared from tumors and normal lung
tissues, using TRIzol reagent (Invitrogen, Carlsbad, CA).
cDNA was generated using SuperScript reverse transcript-
ase (Invitrogen).
Array-CGH
The genomic microarray used contained 3604 BAC
clones representing the human genome at 18 non-gap
chromosome regions (Additional file 2: Table S2).
Clone mapping was analyzed using the BAC end pairs
database of UCSC Genome browser (http://genome.
ucsc.edu/, build 36 - hg18). The BAC library used was
RP-11. The extracted BAC DNA was amplified to 10
μg using Phi29 DNA polymerase reaction (TempliPhi
DNA Sequencing Template Amplification Kit, Amersham,
Princeton, NJ), then digested with DNaseI (New England
Biolabs, Ipswich, MA), and purified with MultiScreen-
PCR Plates (Millipore, Danvers, MA). After digestion, the
DNA fragments were resolved by gel electrophoresis
and the fragment sizes were optimized to within 0.5–3
kb. Finally, the purified BAC DNA fragments were
spotted in triplicate of 72 blocks onto the glass slides
(Corning, NY) with spotting solution (50% DMSO, 50%
dH2O). Representative array images are shown in the
Additional file 3: Figure S1.
Approximately 500 ng of tumor genomic DNA and
reference DNA [for Asian samples: 28 matched-normal
genomic DNA pool; for Caucasian samples: male human
genomic DNA (Promega, Leiden, the Netherlands)] were
labeled by random priming using BioPrime DNA Label-
ing System (Invitrogen) with Cy3-dCTP (reference) or
Cy5-dCTP (tumor). Labeled tumor and reference DNA
were combined together with 100 μg human Cot-1 DNA
(Invitrogen). Hybridization was performed using MAUI
hybridization system (BioMcro Systems, Salt Lake City,
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at 50°C. The arrays were scanned using scanner Gene-
Pix4000B (Axon Instruments, Foster City, CA) and the
images were segmented and transformed to Cy3-Cy5 log
ratio using GenePix software (Axon Instruments, Inc).
Further data processing, including normalization and
data analysis was performed and is described in detail in
the Result section.
Biological software analysis for candidate gene selection
The array results were further analyzed by MetaCore™
analysis software (GeneGo, Inc., St. Joseph, MI) to iden-
tify genes involved in cellular pathways, disease-specific
biomarker genes, and genes annotated in the gene ontol-
ogy databases. Calculation of statistical significance
throughout MetaCore was based on P value, calculated
based on hypergeometric distribution [14]. P value of
0.05 was used for the cutoff of candidate gene selection.
Real-time quantitative polymerase chain reaction (qPCR)
qPCR was used to confirm the array-CGH results and to
determine the DNA copy number variations of identified
candidate genes in 30 NSCLC tumor and corresponding
normal samples from Asian, and 30 NSCLC tumor and
12 autopsy samples from Caucasian. DNA copy number
was quantified by qPCR using the ABI 7900 Sequence
Detection System (PE Applied Biosystems, Foster City,
CA). Genomic DNA (100 ng) was amplified using the
SYBR Green PCR Master Mix (Roche, Palo Alto, CA)
and specific primers for each candidate gene located in
exon and adjacent intron, and the GAPDH internal con-
trol gene located within the promoter region. The pri-
mer sequences and annealing temperature are listed in
the Additional file 4: Table S3. The mean DNA dosage
ratio between each candidate gene and the GAPDH in-
ternal control gene was calculated in all normal and all
tumor samples analyzed [15].
Quantitative reverse transcription polymerase chain
reaction (RT-qPCR)
RT-qPCR was used to measure the mRNA expression of
four candidate genes in 45 NSCLC tumor and the corre-
sponding normal samples from Asian, and 24 tumor and
corresponding normal samples from Caucasian (Tis-
sueScan Lung Cancer Panel IV: HLRT304; OriGene,
Rockville, MD). RT-qPCR was conducted using the ABI
7900 Sequence Detection System (PE Applied Biosys-
tems). Total RNA (4 μg) from tumor and the corre-
sponding normal tissues were reverse transcribed into
cDNA and amplified using the SYBR Green PCR Master
Mix (Roche) and specific primers for each candidate
gene and the ß-actin internal control gene. The primer
sequences and annealing temperature are listed in the
Additional file 4: Table S3. The mean mRNA expressionratio between each candidate gene and the ß-actin in-
ternal control gene was calculated in all normal and all
tumor samples analyzed.
Chromogenic in situ hybridization (CISH)
CISH was done on 4 μm thick formalin-fixed paraffin
embedded tissue section slides following the standard
protocol described in Chang et al. [16]. The probes were
digoxigenin-labeled with BAC DNA (RP11-375N9 and
RP11-170O19 for ARHGAP19 gene probe; RP11-391k6
for ZNF322A gene probe), and then ethanol precipitated
with 10 μg Human Cot-1 DNA. At least 100 non-
overlapping and intact tumor nuclei were evaluated. The
tumor was considered as CISH amplification positive if
the copy number was ≥4 signals per nucleus in more
than 40% of tumor cells evaluated [16].
Immunohistochemistry (IHC)
The protein expression level of the candidate gene,
PAFAH1B1, was evaluated by IHC in 28 NSCLC samples
from Asian and 37 lung cancer samples from Caucasian
tissue array. Paraffin blocks of tumors were cut into 5-μm
slices and then processed using standard deparaffinization
and rehydration techniques. Polyclonal antibody against
PAFAH1B1 (1:800; Novus, Littleton, CO) was used to
detect the protein expression. The evaluation of IHC
was conducted blindly without prior knowledge of the
clinical and pathologic characteristics of the cases.
The samples were graded high expression when >50%
tumor cells were stained positive using adequate
staining in surrounding normal stromal and epithelial
cells.
Statistical analysis
The Bayes regression approach was used to determine
the chromosomal breaking points [17]. Candidate gene
selection by MetaCore (GeneGo, Inc.) was calculated
based on hypergeometric distribution [14] and a P value
of 0.05 was used for the cutoff. A two-tailed t test was
used to determine the statistical significance of differ-
ence in DNA dosage and mRNA expression level of can-
didate genes in clinical samples. Chi-square test was
conducted to examine the association between overex-
pression of candidate genes and clinical pathological
parameters, including sex, age, tumor type, tumor stage,
and smoking. A P < 0.05 was considered to be statisti-
cally significant.
Results
Generation of a specialized non-gapped CGH microarray
representing 18 human chromosome imbalance hotspot
regions
This study constructed a non-gapped BAC array covering
18 human chromosome regions including 2p22.1-p25.1,
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6p12.3-p21.2, 6p22.1-p22.3, 9q21.1-q21.3, 10q21.3-25.1,
12p12.31-13.33, 12q14-q15, 13q12.3-14.2, 17p12-13.3,
17q24.2-25.3, Xp22.11, Xp22.13-22.31, Xq21.31-21.33,
and Xq25-26.1 (see Additional file 2: Table S2). The
chromosomal regions examined in the current array-CGH
showed a high loss of heterozygosity (LOH) frequency in
our previous genome-wide LOH study [13]. To construct
this specialized array, genomic segments fully covering these
18 chromosome regions with 3604 BAC genomic clones
without gaps were mapped. BAC clones were purified, amp-
lified, and arrayed onto glass slides. The homogenous self-
self hybridization image of reference DNA shown in the
Additional file 3: Figure S1 (upper left panel) indicates the
feasibility of our specialized array-CGH.
Block-wise normalization was conducted and a Bayes
regression approach was used to identify the regions
with chromosomal copy number alterations
Tumor DNA from 40 Asian NSCLC patients and 20
Caucasian NSCLC patients were labeled with Cy5 (red
dye) and co-hybridized with reference DNA (for Asian
samples: 28 matched-normal genomic DNA pool; for
Caucasian samples: ten male genomic DNA purchased
from Promega) labeled with Cy3 (green dye) for array-
CGH. Clinical information for the patients is shown
in the Additional file 1: Table S1. A “block-wise
normalization” method, which normalized the array-
CGH data by the log ratio of the self-self hybridization
of reference DNA according to the mean and the stand-
ard deviations of each array block, was established
(lower panel, Additional file 3: Figure S1). The Bayes
regression approach was used to determine the chromo-
somal breakpoints [17]. A region was assigned +1, 0, or
−1 when its gene dosage is higher, uncertain, or lower
than those of its neighbors to define the chromosome
alteration regions (Additional file 3: Figure S1), respect-
ively. Our array-CGH data has been submitted to Gene
Expression Omnibus (GEO) database of NCBI with ac-
cession number GSE21276.
The chromosome regions show high frequency of
chromosomal imbalance and significant correlation with
specific cancer sub-type in Asian and Caucasian lung
cancer patients
The chromosome regions with copy number alteration
in 40 Asian and 20 Caucasian NSCLC patients were
determined. A region with a frequency of gain or loss
greater than 50% was defined as a significant chromo-
somal imbalance region [18,19]. In samples from Asian
lung cancer patients, we have identified eight regions of
chromosomal gain and nine regions of chromosomal
loss (Table 1A) harboring 476 genes (UCSC Genome
browser). In Caucasian lung cancer patients, elevenchromosome regions with frequent gain and nine
regions with frequent loss harboring a total of 459 genes
were identified (Table 1B). Interestingly, seven common
chromosomal imbalance regions harboring 117 genes,
included gain on 3p13-14, 6p22.1, 9q21.13, 13q14.1, and
17p13.3; and loss on 3p22.2-22.3 and 13q13.3 (Table 1A-B)
were found in both Asian and Caucasian patients. In
addition, when tumors were grouped into two major
NSCLC tumor subtypes, adenocarcinoma (ADC) and
squamous cell carcinoma (SCC), six chromosomal imbal-
ance regions showed difference of more than 50% in alter-
ation frequency between ADC and SCC in Asian lung
cancer patients (Table 2A). In Caucasian lung cancer
patients, 14 chromosome regions showed significant differ-
ence between ADC and SCC patients (Table 2B). When
tumors were grouped based on the tumor stage, three
chromosomal imbalance regions with difference of more
than 50% in alteration frequency between early stage
(stages I and II) and late stage (stages III and IV) in Asian
lung cancer patients (Table 3A) were found. In Caucasian
lung cancer patients, five chromosome regions showed
higher alteration frequency in late stage patients than early
stage patients (Table 3B).
The significance of altered biological processes in lung
cancer
We then used Database for Annotation, Visualization
and Integrated Discovery (DAVID) bioinformatics
resources [20] to identify the difference of significantly
altered biological process between Asian and Caucasian
lung cancer patients. The results showed that there were
seven common altered biological processes of gene
ontology between Asian and Caucasian, including cation
transport, metal ion transport, cellular chemical homeo-
stasis, chromatin assembly or disassembly, protein-DNA
complex assembly, nucleosome assembly, and nucleo-
some organization (Figure 1A-B, indicated by * symbol).
In addition, unique altered biological processes including
monovalent inorganic cation transport, protein oligo-
merization, Wnt receptor signaling pathway, regulation
of membrane potential, and response to estrogen stimu-
lus were found in Asian lung cancer patients (Figure 1A).
Unique biological processes in Caucasian included cell
surface receptor linked signal transduction, G-protein
coupled receptor protein signaling pathway, ion homeo-
stasis, cellular cation homeostasis, and chemotaxis
(Figure 1B).
A total of 134 candidate NSCLC-related genes are
selected by MetaCore analysis and integration analysis
with the expression array database
To select potential NSCLC-related genes for further
studies, the following strategy of candidate gene decision
was performed (Figure 2). First, a total of 818 genes
Table 1 Chromosome imbalance regions in lung cancer (alteration frequency > 50%)










3 p13-14.1* 64934270 73536726 8.60 74 Gain: 73% 23
6 p22.1* 26562439 28452189 1.89 60 Gain: 70% 31
9 q21.13* 73445866 76242707 2.80 29 Gain: 70% 8
10 q21.3 69354590 71006065 1.65 15 Gain: 55% 23
10 q24.1 95664566 99431796 3.77 37 Gain: 58% 44
12 p13.31-13.32 2363194 8268165 5.90 44 Gain: 60% 58
13 q14.1-14.2* 42340030 47097431 4.76 38 Gain: 80% 22
17 p13.3* 373082 2754327 2.38 20 Gain: 60% 37
2 p23.2-23.3 25035233 33995335 8.96 75 Loss: 63% 83
2 p24.1 21212355 23783250 2.57 18 Loss: 58% 1
2 q35 215083214 215870969 0.79 9 Loss: 58% 5
3 p21.3-22.3* 33902686 44181635 10.28 82 Loss: 65% 90
4 p15.2-15.31 22255381 24549727 2.29 24 Loss: 60% 5
6 p22.2 23982002 25939112 1.96 68 Loss: 80% 16
12 q15 67646357 69188647 1.54 11 Loss: 55% 11
13 q13.3* 35856763 39003721 3.15 27 Loss: 65% 18
X p22.31 5701499 5872842 0.17 2 Loss: 50% 1
Overall 476
B. Caucasian
2 p24.1-24.3 12723105 21045423 8.32 58 Gain: 55% 21
2 q25.1 11704089 12544967 0.84 7 Gain: 50% 2
3 p12.3-13* 67690502 79574641 11.88 96 Gain: 70% 22
3 p14.1-14.3* 56804094 67550231 10.75 65 Gain: 50% 26
3 p21.31-22.1 42559388 46459596 3.90 33 Gain: 60% 57
3 p25.3-26.3 1711179 9591700 7.88 72 Gain: 55% 20
6 p22.1-22.3* 20951128 28567815 7.62 132 Gain: 60% 97
9 q21.13* 75834015 76513536 0.68 6 Gain: 70% 5
13 q14.1-14.2* 40944092 47097431 6.15 47 Gain: 80% 24
17 p13.2-13.3* 481074 4001084 3.52 13 Gain: 70% 35
X p22.11-22.2 16180300 22691476 6.51 49 Gain: 60% 26
2 p22.3 32854381 33890229 1.04 6 Loss: 50% 3
2 p24.3-25.1 31026798 31813698 0.79 6 Loss: 50% 3
3 p11.1-12.1 84572959 90247330 5.67 46 Loss: 70% 9
3 p22.2-22.3* 32980614 36795763 3.82 13 Loss: 75% 14
3 p23 31259835 32891762 1.63 13 Loss: 60% 10
6 p21.2-22.1 29049491 39602226 10.55 86 Loss: 70% 27
10 p23.1-23.2 82106537 89500949 7.39 79 Loss: 60% 36
12 p12.31 8090287 9190860 1.10 7 Loss: 50% 18
13 q13.3* 35856763 36315193 0.46 5 Loss: 80% 4
Overall 459
a The common alteration regions in both Asian and Caucasian are marked with asterisk (*).
b The information of cytoband start site and end site nucleotide sequences were from UCSC database (http://genome.ucsc.edu/, build 36 - hg18).
c The sizes of cytoband were calculated from the start site to the end site nucleotide sequences.
d The gene number of candidate genes was estimated by “NimbleGen: Transcription_Start_Sites.gff” annotation file (Roche, Palo Alto, CA). The annotation file
indicates all transcription initiation sites for build hg18 as reported in the UCSC Genome browser.
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Table 2 Chromosome imbalance regions with different alteration frequency in relation to tumor subtypes in lung
cancer












2 p24.1 20863719 22199349 1.30 10 Loss :85% Loss :30% 55%
3 p25.2-25.3 9867502 12488641 2.60 18 Loss :25% Gain :40% 65%
6 p22.1 28165236 28452189 0.30 6 Gain :85% Gain :25% 60%
10 q22.3 77428562 79105320 1.70 17 Gain :15% Loss :45% 60%
10 q24.1 98845671 99207113 0.36 4 Gain :50% Gain :70% 20%
17 p13.1 7918593 7993947 0.10 2 Loss :10% Gain :45% 55%
17 q24.2 62769444 63340772 0.60 5 Loss :60% 0 60%
B. Caucasian
2 p23.3 23804032 26257119 2.45 17 Gain :60% 0 60%
3 p11.2-12.1 85893658 87649703 1.76 14 Loss :100% Loss :40% 60%
3 p14.2-14.3 56804094 61897044 5.09 33 Gain :20% Gain :80% 60%
3 p22.2-24.1 29648645 38540543 8.89 25 Loss :70% 0 70%
4 p15.2-15.3 21407638 23952439 2.54 27 0 Loss :80% 80%
6 p12.3 47804985 47961964 0.16 2 0 Gain :60% 60%
6 p22.1-22.2 25985490 26318093 0.33 5 0 Gain :50% 50%
6 q21.1 73325343 73596310 0.27 2 Loss :60% 0 60%
9 q22.2-22.3 76902029 78697046 1.80 17 Loss :50% Gain :20% 70%
10 q21.2 74105644 74697200 0.59 6 0 Gain :60% 60%
12 p13.3 8010296 9309215 1.30 11 Loss :90% Loss :10% 80%
12 q24.2 63460935 64329625 0.87 14 Loss :10% Loss :60% 50%
17 p22.2 15476489 15931167 0.45 4 Gain :60% 0 60%
X q21.3 87836131 89896378 2.06 17 0 Gain :60% 60%
aADC: adenocarcinoma; SCC: squamous cell carcinoma.
Lo et al. BMC Cancer 2012, 12:235 Page 6 of 13
http://www.biomedcentral.com/1471-2407/12/235from Asian and Caucasian databases with chromosome
alteration frequency more than 50% were further ana-
lyzed by MetaCore™ analysis software. Calculation of
statistical significance throughout MetaCore for cellular
pathways, disease-specific biomarker genes, and genes
annotated in the gene ontology databases was based onTable 3 Chromosome imbalance regions with different altera
Chromosome Cytoband Start site End site Size
(Mb
A. Asian
6 p21.2 39548717 39877219 0.32
6 p22.3 21096443 22252887 1.15
17 p13.3 2443685 3461082 1.01
B. Caucasian
2 p22.2-22.3 35262506 36832851 1.57
2 p25.1 8929622 11112217 2.18
3 p24.1-24.3 23113657 26730485 3.62
4 p15.2 25955365 26477816 0.52
10 q24.2-24.3 100717385 104630288 3.91P value, calculated using the hypergeometric distribution
[14]. P value of 0.05 was used for the cutoff of candidate
gene selection. Collectively, 214 genes were selected as
NSCLC-related candidate genes, which are involved in
cell cycle, apoptosis, cell migration, signal transduction,











13 0 Loss :62% 62%
39 0 Gain :66% 66%
9 Gain :21% Gain :71% 50%
11 0 Gain :100% 100%
16 Gain :14% Gain :100% 86%
32 Loss : 7% Loss :60% 53%
4 0 Gain :60% 60%
44 0 Loss :100% 100%
Figure 1 Pie chart of significantly altered biological processes in Asian (A) and Caucasian (B) lung cancer patients. The data were
analyzed by DAVID bioinformatics resources. The common biological processes in both Asian and Caucasian marked with asterisk (*).
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candidate genes analyzed with MetaCore were further
integrated with the expression array for Asian lung can-
cer patients (GEO database with accession number
GSE21933) and the gene expression database of the Na-
tional Cancer Institute's Cancer Genome Anatomy Pro-
ject (http://cgap.nci.nih.gov) for Caucasian lung cancer
patients (see Additional file 5: Table S4). We found 134
genes showing correlation between DNA copy number
and mRNA expression patterns by integrating our array-CGH database with the expression array databases
(Table 4). Finally, we performed literature search and
selected 54 novel lung cancer candidate genes which
have not been reported to be altered in lung cancer. In
the current study, we validated four genes based on
their novelty and antibody availability. These four genes
were ARHGAP19 on 10q24.1 functioning in Rho activity
control, FRAT2 on 10q24.1 involved in Wnt signaling,
PAFAH1B1 on 17p13.3 functioning in motility control,
and ZNF322A on 6p22.1 involved in MAPK pathway
Figure 2 Flowchart summarizing the strategy of candidate
genes selection. First, a total of 818 genes with more than 50%
frequency of chromosome alteration were analyzed by MetaCore
software. Second, the candidate genes analyzed with MetaCore
were further integrated with the gene expression database.
Integrating our array-CGH database with the expression array
databases, 134 genes showing correlation between DNA copy
number and mRNA expression patterns were found. Finally,
literature search was performed to select 54 novel lung cancer
candidate genes for following validation assays at the DNA, and RNA
levels.
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levels.A good correlation is found between array-CGH data and
various validation methods including CISH, qPCR,
RT-qPCR, and IHC
Four methods were employed for gene validation in 147
lung cancer patients. The clinical characteristics and the
validation method conducted for each patient are shown
in the Additional file 1: Table S1. qPCR for DNA copy
number was performed for four candidate genes in
tumors from 30 Asian and 30 Caucasian lung cancer
patients, whose samples were analyzed in array-CGH.
The mean gene dosage of lung cancer candidate genes
ARHGAP19, FRAT2, PAFAH1B1, and ZNF322A in
tumor tissues was significantly higher than the corre-
sponding normal tissues in Asian lung cancer. Gene dos-
age of PAFAH1B1 and ZNF322A was significantly higher
in tumor tissues than autopsy tissues from Caucasian
(Figure 3A). RT-qPCR of the four genes was conductedwith cDNA from tumor and corresponding normal tis-
sues of 45 Asian lung cancer patients. Only two candi-
date genes, PAFAH1B1 and ZNF322A, were analyzed in
tumor and corresponding normal lung tissues from 24
Caucasian lung cancer patients due to the mRNA ina-
vailability. The mean mRNA expression level of all
genes analyzed in the tumor tissues was significantly
higher than in the corresponding normal tissues in
Asian and Caucasian patients (Figure 3B). In addition,
the validation data showed concordant results with
array-CGH.
CISH analysis of patients indicated that copy number
amplification indeed occurred for ARHGAP19 and
ZNF322A genes in lung cancer patients (Figure 4A). To
determine protein expression level of the selected candi-
date genes in lung cancer, IHC was performed for
PAFAH1B1 protein on paraffin blocks from 28 Asian
patients and tissue arrays of Caucasian patients includ-
ing 37 lung cancer patients (Figure 4B). The frequency
of PAFAH1B1 protein overexpression was 68% in Asian
and 70% in Caucasian.
Discussion
Here, we generated a non-gapped specialized CGH
microarray representing 18 human chromosome imbal-
ance hotspot regions in lung cancer. This specialized
CGH array identified the chromosomal regions whose
structural alteration may play critical roles in lung
tumorigenesis. Our array-CGH study provided an in-
valuable database of chromosomal imbalance regions
and candidate genes in Asian and Caucasian lung cancer
patients. CISH, qPCR, RT-qPCR, and IHC were
employed for gene validation of four novel genes with
amplification. The putative lung cancer-related genes
identified in our array-CGH database would help in fur-
ther studies on the mechanism of lung tumorigenesis.
Using the UCSC Genome browser, we have annotated
a total of 476 genes for Asian patients and 459 genes for
Caucasian patients showing high frequency of chromo-
somal imbalance to be our candidate gene database
(Table 1). To improve the validity for identifying poten-
tial cancer-related gene, the genes residing within the
chromosomal imbalance regions were integrated with
gene expression databases. Among the genes selected,
the ion transport and chromatin remodeling are the two
main common biological processes altered in both Asia
and Caucasian populations, suggesting that the candi-
date genes involved in these processes may play import-
ant roles in lung tumorigenesis. For example, irregular
choline transport and metabolism have been involved in
growth arrest and apoptosis in human lung ADC [21].
Dysfunction of histone methylation was also shown to
contribute to human carcinogenesis [22]. Interestingly,
genes involved in Wnt receptor signaling pathway were
Table 4 Candidate genes in lung cancer
Gene namea a-CGH (%) Gene namea a-CGH (%) Gene namea a-CGH (%)
A. Asian
ACAA1 Loss: 65 FRS2 Loss: 55 RPSA Loss: 68
ALDH18A1 Gain: 58 HADHA Loss: 63 RYBP* Gain: 73
ANKRD2 Gain: 58 HELLS Gain: 58 SCGN Loss: 80
APOB Loss: 58 HK1 Gain: 55 SERPINF1 Gain: 60
ARHGAP19 Gain: 60 ING4 Gain: 65 SNRK Loss: 65
AVPI1 Gain: 58 ITGA9 Loss: 65 SPG20 Loss: 65
AXUD1 Loss: 65 LBH Loss: 63 SUCLG2 Gain: 73
BLNK Gain: 58 LRIG1 Gain: 73 TNFRSF1A Gain: 65
CCK Loss: 68 LTBR Gain: 65 TRPC4 Loss: 65
CCNA1 Loss: 80 LYZ Loss: 55 UBE1C* Gain: 73
CRK Gain: 60 MAGI1 Gain: 73 UCN Loss: 63
CTDSPL Loss: 65 MITF* Gain: 73 VAMP1 Gain: 65
CX3CR1 Loss: 65 MLH1 Loss: 65 YWHAE Gain: 60
CYP2C19 Gain: 58 MNT Gain: 60 ZDHHC16 Gain: 58
DLEC1 Loss: 65 MyD88 Loss: 65 ZNF322A* Gain: 70
FKBP4 Gain: 65 PAFAH1B1* Gain: 60 ZNF35 Loss: 65
FOSL2 Loss: 63 PDCD6IP Loss: 65 ZNF384 Gain: 65
FOXM1 Gain: 65 RAD51AP1 Gain: 65
FRAT2 Gain: 58 RPA1 Gain: 60
B. Caucasian
Gene namea a-CGH (%) Gene namea a-CGH (%) Gene namea a-CGH (%) Gene namea a-CGH (%)
ABT1 Gain: 60 HESX1 Gain: 50 PROK2 Gain: 70 VGLL3 Loss: 70
ARF4 Gain: 50 HIST1H1A Gain: 60 PUM2 Gain: 55 WAPAL Loss: 70
ASPA Gain: 65 HIST1H1C Gain: 50 RAD18 Gain: 50 XDH* Loss: 50
CAV3 Gain: 50 HIST1H1D Gain: 50 RBBP7 Gain: 50 YY2 Gain: 60
CCR1 Gain: 60 HIST1H1E Gain: 50 REPS2 Gain: 50 ZBTB47 Gain: 55
CCR5 Gain: 60 HIST1H1T Gain: 50 RhoB Gain: 55 ZFX Gain: 50
CD2AP Gain: 50 HIST1H4B Gain: 60 ROBO1 Gain: 65 ZNF165 Gain: 55
CDCP1 Gain: 60 HIST1H4F Gain: 50 ROBO2 Gain: 70 ZNF167 Gain: 60
CGGBP1 Loss: 80 LMCD1 Gain: 50 RYBP* Gain: 70 ZNF184 Gain: 50
CLEC3B Gain: 60 LTF Gain: 60 SCML1 Gain: 50 ZNF187 Gain: 55
CNTN4 Gain: 55 MBTPS2 Gain: 60 SCML2 Gain: 60 ZNF193 Gain: 55
DCLK3 Loss: 65 MDGA1 Loss: 85 SNCG Loss: 70 ZNF197 Gain: 60
DDX1 Gain: 55 MITF* Gain: 70 SNRK Gain: 60 ZNF322A* Gain: 50
DDX53 Gain: 60 MYCN Gain: 55 SOX4 Gain: 70 ZNF35 Gain: 60
EDEM1 Gain: 50 NT5C1B Gain: 55 SS18L2 Gain: 55 ZNF391 Gain: 50
EIF4E3 Gain: 70 NTSR2 Gain: 50 TMF1 Gain: 70 ZNF445 Gain: 60
ESD Gain: 70 NUFIP1 Gain: 80 TNFSF11 Gain: 80 ZNF452 Gain: 50
FAM107A Gain: 50 PAFAH1B1* Gain: 70 TRPM6 Gain: 60 ZNF501 Gain: 60
FOXJ2 Loss: 50 PGBD1 Gain: 55 TSC22D1 Gain: 90 ZNF502 Gain: 60
FOXP1 Gain: 70 POLA1 Gain: 60 UBE1C* Gain: 70 ZNF660 Gain: 60
GDF7 Gain: 55 PRL Gain: 50 UBP1 Loss: 80 ZNF662 Gain: 60
a The common cancer-related genes in both Asian and Caucasian are labeled with asterisk (*), and the detailed description of all genes is shown in Additional file 5:
Table S4.
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Figure 3 DNA copy number validation by qPCR (A) and mRNA expression validation by RT-qPCR (B) of four candidate genes in clinical
samples. The Y-axis is the mean DNA dosage ratio (A) or mean mRNA expression ratio (B) between candidate gene and the internal control
gene in all samples analyzed. The P values of comparison between normal (N) and tumor (T) samples for each gene is as indicated.
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cancer was addictive to cell surface receptor linked sig-
nal transduction and G-protein coupled receptor protein
signaling pathways (Figure 1A-B). Genes involved in
these pathways warrant further studies.
This study found several candidate genes which are
located in the common chromosome alteration regions
in both Asian and Caucasian, such as PAFAH1B1 gene
on 17p13.3. In array-CGH data, chromosome region
17p13.3 harboring PAFAH1B1 showed gain of copy
number in 60% of Asian and 70% of Caucasian patients
(Table 1). In addition, PAFAH1B1 DNA copy number
and mRNA expression level in tumor tissues was sig-
nificantly higher than that of the matched-normal
tissues in both Asian and Caucasian lung cancer patients
(Figure 3). The frequency of PAFAH1B1 protein overex-
pression was 68% in Asian and 70% in Caucasian(Figure 4). Interestingly, chromosome region 17p13.3
harboring PAFAH1B1 gene also demonstrated associ-
ation with advanced tumor stage in array-CGH data
(Table 3A). Overexpression of PAFAH1B1 mRNA was
found in 59.1% of early-stage and 78.3% of late-stage lung
cancer patients of Asian descent (Additional file 6:
Table S5), suggesting that the alteration of PAFAH1B1
gene may be involved in both tumor initiation and pro-
gression. More patients will be analyzed to clarify its
tumorigenic role.
We also found several candidate genes showing differ-
ent alteration frequency between Asian and Caucasian
patients, such as ARHGAP19 and FRAT2. These two
closely located (within a 39.8 kb region at 10q24.1) can-
didate genes, showed alteration frequency of 57.5% with
gain of gene copy number in Asian (Table 1A), whereas
the alteration frequency was only 20% in Caucasian
Figure 4 DNA copy number and protein expression level validation in specimens from lung cancer patients. (A) Representative CISH
images of ARHGAP19 and ZNF322A genes in paraffin-embedded lung tumor tissue. Images taken from tumor without gene copy number
amplification (left) and with gene copy number amplification (right). The enlarged image of one nucleus is shown on the lower right corner. CISH
images: 400X magnification. (B) Representative IHC images of PAFAH1B1 protein in tissue array. Patients with protein overexpression are indicated
by + symbol. Patients with normal expression are indicated by – symbol. IHC images: 200X magnification.
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firmed significant gene amplification and mRNA overex-
pression in tumors from Asian but not from Caucasian
lung cancer patients (Figure 3A-B). Interestingly, in rela-
tion to clinical pathological parameters of Asian lung
cancer patients, mRNA overexpression of ARHGAP19
and FRAT2 was significantly associated with lung SCC
(Additional file 6: Table S5). ARHGAP19 encodes a Rho
GTPase-activating protein that stimulates the intrinsic
GTP hydrolysis activity of Rho family proteins [23].
ARHGAP family genes are considered to be cancer-
associated genes because their genetic alterations lead to
carcinogenesis through the dysregulation of Rho/Rac/
Cdc42-like GTPases [24]. The up-regulation of the
FRAT2 gene has been reported in human gastric cancer
[25] and has been implicated in carcinogenesis through
activation of the Wnt signaling pathway [26]. Our previ-
ous study showed that more than 50% of Taiwanese lung
cancer patients had alterations in proteins involved in
Wnt/β-catenin signaling [27]. It is important to investi-
gate the role of ARHGAP19 and FRAT2 alterations in
SCC lung tumorigenesis and their correlations with Rho
and Wnt signaling pathways.
Interestingly, ZNF322A on 6p22.1 showed significant
gene amplification and mRNA overexpression in Cauca-
sian, and borderline significant in Asian lung cancer
patients (Figure 3). The DNA copy number validation
for ZNF322A gene was lower than the array CGH result
because the BAC may harbor some other genes in
addition to ZNF322A. ZNF322A has been reported to be
a novel human C2H2 Krüppel-like zinc-finger protein,
which regulates transcriptional activation in the MAPKsignaling pathways. The Krüppel zinc-finger protein is
involved in the regulation of normal cell growth, differ-
entiation, embryogenesis, and tumorigenesis [28]. Identi-
fication of the role of ZNF322A in lung tumorigenesis is
worthy of further study.
Note that no common tumor subtype-specific regions for
ADC and SCC were found in Asian and Caucasian lung
cancer patients when the genomic alteration profiles were
compared (Table 2A). Even in the same racial group, ex-
treme difference of chromosome alterations could occur
between ADC and SCC. These data implicated that distinct
etiological mechanism in addition to tobacco and environ-
mental exposures are involved in lung cancer of Asian from
Caucasian, supporting the epidemiologic observation that
lung cancer in Asian shows relatively high percentage of
non-smoking female ADC. Notably, Broët et al. [29] identi-
fied molecular differences between NSCLCs from East-
Asian and Western European patients by using single
nucleotide polymorphism microarray platform, and
revealed several copy number aberrations significantly
associated with ethnicity (gain on 1p36, 16p13, 16p12, and
16p11 in East-Asian; loss on 19p13 in Western European
patients), EGFR mutation (gain on 1p36, 1p35, 7p22-21,
7p15-12, 14q31-32, 16p13, and 16p12 in EGFR mutant
tumors; loss on 21q21-22 in EGFR wild-type tumors), but
not to K-ras or p53 mutations. Correlation of the muta-
tional spectrum of EGFR, K-ras, p53, and ALK genes to
our array-CGH data warrants further investigations.
Conclusions
In conclusion, our specialized array-CGH results provide
an invaluable database of specific chromosome regions
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ferential in Caucasian and Asian lung cancer patients.
Functional studies using cell, animal, and clinical models
will be conducted to identify their cellular functions and
etiological roles in lung tumorigenesis.
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